PHOTO
Dubai, United Arab Emirates: Wockhardt, a research-based global pharmaceutical and biotech company, is expanding into the Middle East by setting up its first manufacturing facility in Jebel Ali Free Zone (Jafza) in Dubai.
The US$40 million state-of-the-art facility will be specifically used for manufacturing New Chemical Entities (NCEs) catering to global markets.
Speaking at the inauguration of the new facility, Dr. Habil Khorakiwala, Founder Chairman of Wockhardt, said the company is poised to make a major breakthrough in the development of antimicrobial drugs to fight the emerging threat of superbugs.
“With Wockhardt’s commitment to R&D, we have five breakthrough NCEs that have been accorded Qualified Infectious Disease Product (QIDP) status by US FDA. With the new facility in the Middle East, we aim to focus on our commitment in developing medicines that can fight antimicrobial resistance,” says Dr. Habil Khorakiwala.
Antimicrobial Resistance (AMR) - the ability of infections to resist antibiotics to work against it - is increasingly recognised as a growing global health problem. Infections caused by antimicrobial-resistant strains of bacteria - also called ‘superbugs’ - are unlikely to respond to standard treatments resulting in prolonged illness and a greater risk to health, and severely impacting clinical outcomes, leading to further higher healthcare costs due to consumption of healthcare resources.
Dr. Mahesh Patel, Chief Scientific Officer of New Drug Discovery, Wockhardt says, “Wockhardt’s drug discovery program has immensely benefited from global collaborations with universities and scientists of international repute in the areas of public health, Infectious diseases and clinical microbiology”.
Wockhardt currently has five novel antibiotic drugs in advanced stages of global clinical development which will be effective against these “superbugs” threats identified by the Center of Disease Control, USA. Considering the strategic importance of these antibiotics, the US FDA has granted Qualified Infectious Disease Program (QIDP) status to the five novel antibiotic drugs.
“Wockhardt has dedicated significant resources for the discovery and development of these novel antibiotics, which are in advanced stages of development are a culmination of 20 years of dedicated and focused research”, said Dr. Murtaza Khorakiwala, Managing Director of Wockhardt.
The 10,000 sq.m facility in Dubai is equipped with best-in-class and fully automated manufacturing equipment, creating a self-sufficient environment for handling, warehousing, manufacturing operations, product testing and product stability.
“The facility will work on the exhibit batches and will be offered for inspection by the regulators at an appropriate time”, he further added.
The facility meets the needs of Aseptic Dry Powder Injectable manufacturing and filling with a high-quality operation. This facility is dedicated to launch its novel New Chemical Entities in the antibiotics segment to the world from UAE.
“Wockhardt conducted extensive studies for identifying a region in the Middle East to establish a strong manufacturing presence for its advanced patented drugs. JAFZA was found to be appropriate for the factory premises for manufacturing patented proprietary drugs for global markets”, adds Dr. Murtaza Khorakiwala. Jafza is home to 306 healthcare and pharmaceutical companies from 54 countries.
UAE's pharmaceutical and healthcare market is expected to increase by an additional AED12.45 billion from 2019 to 2021.
According to a report by BMI research, the UAE’s pharmaceutical and healthcare markets are among the region’s best-performers, growing from AED62.30 billion in 2017 to AED65.68 billion in 2018 and AED78.13 billion in 2021.
Sultan Bin Sulayem, Group Chairman and CEO, DP World, said, “The healthcare and pharmaceutical sectors are key strategic targets in the Dubai Industrial Strategy 2030. As a trade and logistics hub, Jafza fully supports this vision and we are determined to help it grow.
“We warmly welcome Wockhardt to Jebel Ali Free Zone. The opening of a research-centric global pharmaceutical and biotech company like Wockhardt in Jafza marks another milestone moment in our efforts to encourage pharmaceutical companies to establish their manufacturing facilities, as well as knowledge and R&D centres in DP World’s business and industrial parks.”
Wockhardt Bio AG manufacturing facility is designed to meet the standards of various international regulatory agencies and the standards set by the Local Ministry of Health.
“Wockhardt is poised for a quantum leap into the future. It is a future of dynamic changes, exciting possibilities and endless potential to further its goal of ‘Life Wins’ and Wockhardt is committed to shaping this future," adds Dr. Habil Khorakiwala.
About Wockhardt:
Wockhardt is a global pharmaceutical and biotech company employing over 9,000 people and 27 nationalities with presence in the USA, UK, Ireland, Switzerland, France, Mexico, Russia and many other countries. It has manufacturing and research facilities in India, the USA & UK and a manufacturing facility in Ireland. Wockhardt has a significant presence in the USA, Europe and India, with 62% of its global revenues coming from international businesses. Wockhardt is home to 600 plus scientists, of whom, 70 plus are doctorates. Wockhardt is the only company in the world where USFDA has given QIDP Status (Qualified Infectious Diseases Programme) for five of its Antibacterial discovery programmes – two of them are Gram Negative and three Gram Positive effective against untreatable ‘Superbugs’. Wockhardt’s entire Anti-infective portfolio particularly addresses the specific bacterial organism where resistances are high and breakthrough antibiotics are needed.
About Jebel Ali Free Zone (Jafza)
Jebel Ali Free Zone (Jafza) is one of the world’s leading free trade zones. A DP World-owned company, the free zone was created in 1985 to promote trade and support container throughput at the Jebel Ali Port. Today, it is one of the largest free zones globally and the region’s most efficient logistics hub. Located in Dubai, United Arab Emirates, between the world’s most productive container terminal, Jebel Ali Port, and Al Maktoum International Airport, Jafza provides the best in multi-modal connectivity.
Jafza accounts for almost 32% of total FDI (Foreign Direct Investment) flow into the country. The free zone contributes 21% of Dubai’s GDP on a yearly basis and it sustains the employment of more than 135,000 people in the United Arab Emirates. In 2017, Jafza generated trade worth USD 83.1 billion.
As the leading business hub between Asia, Europe and Africa, the fastest growing producing and consumer markets globally, with over 30 years’ experience, Jafza focuses on long-term customer relationships. Jafza builds alliances with global investors by providing them with world-class infrastructure and support, plus quality-driven value-added services and incentives. Jafza enables its customers to access huge business opportunities in the region with ease and efficiency.
© Press Release 2018Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
